Droz Jean-Pierre, Boyle Helen, Culine Stéphane, Fizazi Karim, Fléchon Aude, Massard Christophe
Université Claude-Bernard - Lyon-I, centre Léon-Bérard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.
Hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Bull Cancer. 2013 Dec;100(12):1319-32. doi: 10.1684/bdc.2013.1863.
Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose chemotherapy). Clinical stage I testicular cancer is the most common presentation and different strategies are proposed: adjuvant therapies, surgery or surveillance. During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs.
生殖细胞肿瘤（GCTs）是年轻男性中最常见的癌症类型。自20世纪70年代末以来，播散性GCT一直是可治愈转移性癌症的典范，转移性GCT通过以顺铂为基础的化疗，随后对残留肿块进行手术切除，具有很高的治愈率。目前使用国际生殖细胞共识分类（IGCCC）评估患者的预后，并据此调整化疗负担。约20%的患者在一线以顺铂为基础的化疗后仍未治愈，需要挽救性化疗（高剂量或标准剂量化疗）。临床I期睾丸癌是最常见的表现形式，目前提出了不同的治疗策略：辅助治疗、手术或监测。在过去三十年中，临床试验和强大的国际合作促成了GCTs管理方面的共识。
